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Once upon a time, there were diseases for which patients
had to die without cure and to be treated only to relieve
or retard symptoms, such as diabetes, myocardial infarction,
postsurgical bronchopleural fistulas, Parkinson’s disease, and
Alzheimer’s disease.
Then stem cells started to be intensively studied for
infusion or transplantation into tissues for purposes of
repair, revascularization, and other therapeutic actions [1,
2]. After systemic or local administration, stem cells may
proliferate, migrate, and repopulate pathologic sites, bringing
remarkable therapeutic effect. Indeed, several studies have
demonstrated the capacity of adult stem cell transplantation
to restore/induce bone repair and revascularization of the
ischemic cardiac tissue in vivo, while investigations are
underway on tissue neuroregeneration in disorders such as
Parkinson’s and Alzheimer’s disease and diseases of the lung
and airways [3–5], liver [6], diabetes, and other organs.
A risk that has been identified in early stem cell studies
lays in the ability of undifferentiated human embryonic stem
cells to produce tumors in vivo, such as teratomas and
teratocarcinomas [7]. As a result, stem cell misbehavior after
delivery has been regarded as a major obstacle for translation
of stem cell-based therapies into clinical reality.
Furthermore, it has been demonstrated that, when
injected systemically, mesenchymal stromal cells (MSCs)
accumulate in the lungs and capillary beds of other tissues,
thus decreasing the number of MSCs migrating to target
areas for treatment [8]. Molecular imaging can offer a
better understanding of cell fate after transplantation, thus
providing successful implementation of cell therapies.
For instance, J. Cao et al. demonstrated allogenic bone
marrow MSCs home to the dorsal skin, apart from the lungs
and kidneys, after tail-vein-injection, could not be detected
14 days later. M. Song et al. were able to track systemically
transplanted human bone marrow-derived mesenchymal
stromal cells mice with smoke inhalation injury through
BLI, eventually demonstrating that MSC xenografts repaired
smoke inhalation-induced lung injury in mice.
Magnetic Resonance Imaging (MRI), Positron Emis-
sion Tomography (PET), Single-Photon Emission Computed
Tomography (SPECT), Fluorescence Imaging (FLI), and
Bioluminescence Imaging (BLI) are multiple examples of
imaging systems that can visualize signals generated form
labelled cells, thus providing accurate and detailed informa-
tion about cell fate, migration, and engraftment following
transplantation.
In the specific setting of MRI, X.-G. Peng et al. demon-
strated that Diffusion Tensor Imaging could be a useful
tool for noninvasive evaluation of muscle tissue damage and
repair in animal models and patient with ischemic diseases,
while X. Chen et al. demonstrated that iron particles are
not a reliable marker for in vivo tracking the fate of MSCs
engraftment in case of myocardial infarction.
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Cell tracking can be performed either by molecular
probes entering the target cell by active/passive transport or
by overexpression of reporter genes integrating into cellular
genome [9].
As demonstrated by R. Donders et al., two-photon confo-
cal laser scanning microscopy (TPM) and second harmonic
generation (SHG) are alternative techniques that may enable
the detection of cells and extracellular structures, based on
intrinsic properties of the specific tissue and intracellular
molecules under optical irradiation.
Molecular imaging may also play a role in defining the
proper cell type, delivery method, cell dose, therapeutic win-
dow, and evaluation of toxicity to patients, by identification
of early transformation of cell grafts into tumors, as well as
imaging the proliferation and/or expression of tumor-specific
markers, which cannot be detected by traditional imaging
techniques.
Moreover, in vivo imaging of stem cells may disclose how
cells survive and proliferate within the target tissue, as well as
their differentiation and maturation, thus providing precious
data to generate a dose-response curve to identify the optimal
dose and dosing frequency of cell therapies [9].
For instance, in the specific setting of stem cell transplan-
tation for liver diseases, there have been two main clinical
applications ofmolecular imaging [10, 11]. In this special issue
of this journal, the multiple possibilities of monitoring stem
cell transplantation for liver diseases have been extensively
exposed in a review article by P. Wang et al.
However, the serial visualization and tracking of trans-
planted stem cells, including their possible migration and/or
retention in other sites, are still issues to be resolved before
preclinical studies can be turned into clinical studies. For
example, ultrasound-guided intralesional injection of MSCs
is held as the benchmark for cell delivery in tendonitis
because many reports have determined that local injury
retains cells within a small radius of the site of injection.
However, in this issue, A. Scharf et al. have demonstrated that
there is a greater delocalization than expected, and relatively
few cells are retained within collagenous tendon compared
to surrounding fascia, underlying the need of further in vivo
studies.
Similar issues are still unsolved about the use of extra-
cellular vesicles (EVs), considered as paracrine mediators of
the beneficial effects on tissue remodeling associated with
cell therapy. The administration of MSCs-derived EVs may
have the potential to open new and safer therapeutic avenues,
alternative to cell-based approaches, for degenerative dis-
eases, but studies about the biodistribution upon systemic
delivery of EVs indicate in liver, spleen, and lungs preferential
target organs. With this regard, G. Di Rocco et al. reviewed
the existing strategies for in vivo tracking and targeting of
EVs isolated from different cellular sources and the studies
elucidating the biodistribution of exogenously administered
EVs.
Although many examples of in vitro and in vivo studies
have already been published, clinical applications of molecu-
lar imaging in stem cells therapies are still limited.
At the moment we are writing in the US more than
3,900 clinical trials with “stem cell transplantation” registered
(https://www.clinicaltrials.gov), 1,384 of which are open and
are recruiting. Therefore, it is our opinion that in the
forthcoming years the application of cell tracking studies
in clinical research will dramatically increase and that the
information gathered through cellular and molecular imag-
ing techniques will play an important role in clinical trials
design, in monitoring the cell delivery, in defining the fate of
the transplantation, in interpreting the clinical data, and in
understanding the reasons of success or failure of the trials.
After further evaluation of different possibilities of track-
ing stem cells, we do expect that many clinical questions,
raised from applications of stem cells-based therapies, will
find an answer inmolecular imaging.Therefore, we do believe
that stem cell-based therapies andmolecular imagingwill live
together happily ever after.
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